

# Lingzhi Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/280100/publications.pdf>

Version: 2024-02-01

101  
papers

5,427  
citations

71102

41  
h-index

95266

68  
g-index

103  
all docs

103  
docs citations

103  
times ranked

7737  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. <i>Seminars in Cancer Biology</i> , 2022, 80, 379-390.	9.6	87
2	Bacteria as a treasure house of secondary metabolites with anticancer potential. <i>Seminars in Cancer Biology</i> , 2022, 86, 998-1013.	9.6	29
3	Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer. <i>Cancer Letters</i> , 2022, 524, 91-102.	7.2	38
4	The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy. <i>Theranostics</i> , 2022, 12, 87-104.	10.0	54
5	CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3. <i>Cancer Letters</i> , 2022, 532, 215586.	7.2	15
6	Noncoding RNAs of Extracellular Vesicles in Tumor Angiogenesis: From Biological Functions to Clinical Significance. <i>Cells</i> , 2022, 11, 947.	4.1	7
7	Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. <i>Biomarker Research</i> , 2022, 10, 10.	6.8	27
8	Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2248-2256.	7.0	3
9	Hypoxia-Induced circRNAs in Human Diseases: From Mechanisms to Potential Applications. <i>Cells</i> , 2022, 11, 1381.	4.1	3
10	Non-coding RNA-based regulation of inflammation. <i>Seminars in Immunology</i> , 2022, 59, 101606.	5.6	40
11	Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1124-1131.	1.0	8
12	PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 1875-1881.	7.0	40
13	Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1484-1497.	5.4	55
14	The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1291-1336.	10.5	68
15	The double-edged sword of H19 lncRNA: Insights into cancer therapy. <i>Cancer Letters</i> , 2021, 500, 253-262.	7.2	56
16	Putting the BRK on breast cancer: From molecular target to therapeutics. <i>Theranostics</i> , 2021, 11, 1115-1128.	10.0	14
17	Epstein-Barr virus (EBV) encoded microRNA BART8 $\beta$ drives radioresistance-associated metastasis in nasopharyngeal carcinoma. <i>Journal of Cellular Physiology</i> , 2021, 236, 6457-6471.	4.1	9
18	Characterization and Establishment of a Novel EBV Strain Simultaneously Associated With Nasopharyngeal Carcinoma and B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 626659.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma. <i>Oncogene</i> , 2021, 40, 3101-3117.	5.9	18
20	Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 3567-3581.	2.8	3
21	Diosgenin attenuates tumor growth and metastasis in transgenic prostate cancer mouse model by negatively regulating both NF- $\kappa$ B/STAT3 signaling cascades. <i>European Journal of Pharmacology</i> , 2021, 906, 174274.	3.5	21
22	Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?. <i>Seminars in Cancer Biology</i> , 2021, 74, 105-120.	9.6	36
23	Epigenetic derepression converts PPAR $\delta$ into a druggable target in triple-negative and endocrine-resistant breast cancers. <i>Cell Death Discovery</i> , 2021, 7, 265.	4.7	7
24	Resveratrol for cancer therapy: Challenges and future perspectives. <i>Cancer Letters</i> , 2021, 515, 63-72.	7.2	164
25	Celastrol in cancer therapy: Recent developments, challenges and prospects. <i>Cancer Letters</i> , 2021, 521, 252-267.	7.2	50
26	Circular RNAs in cell cycle regulation: Mechanisms to clinical significance. <i>Cell Proliferation</i> , 2021, 54, e13143.	5.3	27
27	Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?. <i>Frontiers in Pharmacology</i> , 2021, 12, 828856.	3.5	19
28	Targeting Cell Metabolism as Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 285-308.	5.4	32
29	A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. <i>BMC Cancer</i> , 2020, 20, 1118.	2.6	5
30	Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5320-5328.	7.0	14
31	Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4831.	3.8	69
32	&lt;p&gt;CYLD Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Regulating NDRG1&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 10639-10649.	1.9	6
33	A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. <i>Pharmacological Research</i> , 2020, 156, 104686.	7.1	61
34	Optical and Near-infrared Observations of the Nearby SN Ia 2017cbv. <i>Astrophysical Journal</i> , 2020, 904, 14.	4.5	12
35	A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. <i>Oncogenesis</i> , 2019, 8, 65.	4.9	18
36	MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2019, 134, 2046-2058.	1.4	25

#	ARTICLE	IF	CITATIONS
37	EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM/ATR signaling pathway. <i>Bioscience Reports</i> , 2019, 39, .	2.4	25
38	Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition. <i>Cells</i> , 2019, 8, 1178.	4.1	151
39	FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway. <i>Cancers</i> , 2019, 11, 836.	3.7	12
40	Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. <i>Cancer</i> , 2019, 125, 1789-1798.	4.1	26
41	Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors. <i>Redox Biology</i> , 2019, 25, 101073.	9.0	90
42	Role of tumor-derived exosomes in cancer metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 12-19.	7.4	82
43	The expanding roles of long non-coding RNAs in the regulation of cancer stem cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 108, 17-20.	2.8	78
44	Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43-mediated gap junction intercellular communication. <i>International Journal of Oncology</i> , 2018, 52, 295-304.	3.3	10
45	Molecular targets and anti-cancer potential of escin. <i>Cancer Letters</i> , 2018, 422, 1-8.	7.2	52
46	Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling. <i>Cancer Letters</i> , 2018, 417, 152-160.	7.2	69
47	Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. <i>Cancer Letters</i> , 2018, 416, 75-86.	7.2	120
48	Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of <i>Nigella sativa</i> Linn. <i>Pharmacological Research</i> , 2018, 129, 357-364.	7.1	54
49	A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs. <i>Pharmaceutics</i> , 2018, 10, 221.	4.5	42
50	TIPE Family of Proteins and Its Implications in Different Chronic Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2974.	4.1	58
51	Sorcin a Potential Molecular Target for Cancer Therapy. <i>Translational Oncology</i> , 2018, 11, 1379-1389.	3.7	56
52	Potential role of genipin in cancer therapy. <i>Pharmacological Research</i> , 2018, 133, 195-200.	7.1	98
53	Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of <i>Nigella sativa</i> Linn. <i>Pharmacological Research</i> , 2018, 133, 213-214.	7.1	3
54	Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 9.	17.1	29

#	ARTICLE	IF	CITATIONS
55	A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study. <i>Pharmaceutics</i> , 2018, 10, 123.	4.5	8
56	Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. <i>Scientific Reports</i> , 2018, 8, 12248.	3.3	72
57	Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges. <i>Trends in Biotechnology</i> , 2017, 35, 665-676.	9.3	313
58	Variable Stars Observed in the Galactic Disk by AST3-1 from Dome A, Antarctica. <i>Astronomical Journal</i> , 2017, 153, 104.	4.7	18
59	Non-malignant epithelial cells preferentially proliferate from nasopharyngeal carcinoma biopsy cultured under conditionally reprogrammed conditions. <i>Scientific Reports</i> , 2017, 7, 17359.	3.3	21
60	A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 12831-12842.	1.8	82
61	Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1. <i>Oncotarget</i> , 2017, 8, 41572-41581.	1.8	9
62	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , 2016, 1, e87607.	5.0	44
63	Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. <i>PLoS ONE</i> , 2016, 11, e0147681.	2.5	7
64	Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. <i>Oncotarget</i> , 2016, 7, 44790-44802.	1.8	51
65	Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours. <i>Scientific Reports</i> , 2016, 6, 27826.	3.3	11
66	Exosome-Mediated Metastasis: From Epithelial to Mesenchymal Transition to Escape from Immunosurveillance. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 606-617.	8.7	393
67	A novel combinatorial strategy using Seliciclib and Belinostat for eradication of non-small cell lung cancer via apoptosis induction and BID activation. <i>Cancer Letters</i> , 2016, 381, 49-57.	7.2	41
68	Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2966-2976.	4.1	86
69	Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 575-589.	5.4	146
70	Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. <i>Cancer Science</i> , 2016, 107, 173-180.	3.9	6
71	Targeting transcription factor STAT3 for cancer prevention and therapy. , 2016, 162, 86-97.		225
72	Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. <i>Oncotarget</i> , 2016, 7, 64089-64099.	1.8	16

#	ARTICLE	IF	CITATIONS
73	PHOTOMETRY OF VARIABLE STARS FROM THE THU-NAOC TRANSIENT SURVEY. I. THE FIRST TWO YEARS. <i>Astronomical Journal</i> , 2015, 150, 107.	4.7	10
74	Simvastatin protects Sertoli cells against cisplatin cytotoxicity through enhanced gap junction intercellular communication. <i>Oncology Reports</i> , 2015, 34, 2133-2141.	2.6	7
75	Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. <i>Molecular Oncology</i> , 2015, 9, 818-833.	4.6	100
76	Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. <i>Cancer Letters</i> , 2015, 362, 8-14.	7.2	140
77	Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17 <sup>12</sup> -Hydroxyexemestane and 17 <sup>12</sup> -Hydroxyexemestane-17-O- <sup>12</sup> -D-Glucuronide: Application to Human Pharmacokinetics Study. <i>PLoS ONE</i> , 2015, 10, e0118553.	2.5	11
78	Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. <i>Oncotarget</i> , 2015, 6, 5147-5163.	1.8	79
79	Simvastatin-induced up-regulation of gap junctions composed of connexin 43 sensitize Leydig tumor cells to etoposide: An involvement of PKC pathway. <i>Toxicology</i> , 2013, 312, 149-157.	4.2	19
80	PHOTOMETRY OF VARIABLE STARS FROM DOME A, ANTARCTICA: RESULTS FROM THE 2010 OBSERVING SEASON. <i>Astronomical Journal</i> , 2013, 146, 139.	4.7	43
81	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013, 5, 1051-1066.	6.9	235
82	Quantification of L-cystathionine in human plasma and erythrocytes by liquid chromatography-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2013, 48, 406-412.	1.6	18
83	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e54522.	2.5	46
84	Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. <i>Cell</i> , 2012, 150, 575-589.	28.9	136
85	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 3361-3367.	1.6	167
86	Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 61, 86-92.	2.8	59
87	Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4090-4095.	3.2	30
88	Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. <i>Journal of Mass Spectrometry</i> , 2011, 46, 202-208.	1.6	13
89	Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2155-2161.	2.3	30
90	PHOTOMETRY OF VARIABLE STARS FROM DOME A, ANTARCTICA. <i>Astronomical Journal</i> , 2011, 142, 155.	4.7	41

#	ARTICLE	IF	CITATIONS
91	Abstract C54: The identification of cisplatin resistance pathways in lung squamous cell carcinoma and approaches to overcome resistance. , 2011, , .		0
92	A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2409-2414.	2.3	8
93	Cisplatin and Oxaliplatin Inhibit Gap Junctional Communication by Direct Action and by Reduction of Connexin Expression, Thereby Counteracting Cytotoxic Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 903-911.	2.5	42
94	Abstract 1034: Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high Bcl-2 expression. , 2010, , .		0
95	Tramadol and Flurbiprofen Depress the Cytotoxicity of Cisplatin via Their Effects on Gap Junctions. Clinical Cancer Research, 2009, 15, 5803-5810.	7.0	53
96	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Investigational New Drugs, 2008, 26, 169-173.	2.6	142
97	A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2008, 62, 243-251.	2.3	14
98	Does saturable formation of gemcitabine triphosphate occur in patients?. Cancer Chemotherapy and Pharmacology, 2008, 63, 55-64.	2.3	21
99	A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2008, 14, 4213-4218.	7.0	67
100	Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neuroscience Letters, 2006, 408, 189-193.	2.1	26
101	A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clinical Pharmacology and Therapeutics, 2006, 80, 346-355.	4.7	124